Blood Sugar Coating Changes in Serum May Flag Alzheimer's Before Symptoms Appear

Alzheimer's disease (AD) affects roughly 55 million people worldwide, with projections suggesting that number could reach 140 million by 2050. One of the greatest unmet needs in the field is reliable, accessible early detection—particularly the ability to identify individuals in the pre-dementia Mild Cognitive Impairment (MCI) stage before irreversible neurological damage accumulates. Current clinical diagnosis relies heavily on behavioral assessment and expensive or invasive tools like PET imaging or cerebrospinal fluid analysis. Blood-based biomarkers represent a critical frontier.

This study from Texas Tech University and collaborating institutions tackled this challenge through glycomics—the systematic profiling of glycans, the complex sugar chains attached to proteins. Using serum samples from 64 participants (28 cognitively normal controls, 10 with non-amnestic MCI, 14 with amnestic MCI, and 12 with AD dementia) collected through the Michigan Alzheimer's Disease Research Center, researchers applied highly sensitive nano-LC-MS/MS on a C18 column to identify and quantify N-glycans. A second analytical platform using an in-house mesoporous graphitized carbon (MGC) column was employed specifically to resolve structurally similar N-glycan isomers, which are invisible to most conventional methods.

The analysis identified 99 unique N-glycans across all groups. Key findings showed that sialylation—the addition of sialic acid residues to glycan chains—was significantly upregulated in AD compared to controls and MCI groups, while fucosylation was markedly downregulated. These changes align with known roles of sialic acid in neuroinflammation and cell signaling, and of fucose in immune modulation and protein folding. Distinct glycan expression patterns were observed at each stage of cognitive decline, suggesting that the serum N-glycome changes in a progressive, stage-dependent manner.

Perhaps most novel was the isomeric analysis. Using the MGC column, the team identified specific N-glycan isomers capable of distinguishing non-amnestic MCI (naMCI, which tends to progress to non-Alzheimer's dementia) from amnestic MCI (aMCI, which carries high risk of progressing to AD). Additionally, certain isomers tracked the progression from aMCI to AD dementia. This is reported as the first study to examine N-glycan isomerism in the context of AD and MCI subtypes. Parallel Reaction Monitoring (PRM)-MS was also employed to validate the differential expression of the identified glycans, adding analytical rigor. These glycan biomarkers could complement existing protein-based markers like amyloid-beta and tau, offering a richer and potentially earlier diagnostic signal.